Acute Porphyria Drugs

Monograph

G04CA03 - Terazosin
Propably not porphyrinogenic
PNP

Rationale
No data pointing to CYP-interaction. Two references authorised / use with care.
Chemical description
Used in hypertrophic prostatic disease, 2-5 mg/d. Quinazoline derivative with selective effect on alpha-1-receptors in the bladder, giving rise to relaxation. Metabolized in the liver by hydrolysis and demethylation. No data pointing to CYP-interaction. South African list: use with care. French list: authorized
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes G04C / G04CA or go back.
References
Tradenames

Hytrin · Terazosine Hytrin · Terazosab · Terazosine Alfaprost · Deflox · Magnurol · Mayul · Sutif · Terazosina · Zayasel Setegis Prostatil · Terafluss · Teraprost · Terazosina · Unoprost · Urodie · Uroflus Hytrin BPH Benph · Hytrin · Hytrin BPH · Terazosin Sinalfa Heitrin · Hytrin · Sinalfa · Terablock Hytrin · Kornam Hytrin · Terazosab Terazosin Kornam Kornam Terazosine Terazosina Terazosin
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙